作者
M Eugenia Dieterle, Denise Haslwanter, Robert H Bortz III, Ariel S Wirchnianski, Gorka Lasso, Olivia Vergnolle, Shawn A Abbasi, J Maximilian Fels, Ethan Laudermilch, Catalina Florez, Amanda Mengotto, Duncan Kimmel, Ryan J Malonis, George Georgiev, Jose Quiroz, Jason Barnhill, Liise-anne Pirofski, Johanna P Daily, John M Dye, Jonathan R Lai, Andrew S Herbert, Kartik Chandran, Rohit K Jangra
发表日期
2020/9/9
期刊
Cell host & microbe
卷号
28
期号
3
页码范围
486-496. e6
出版商
Cell Press
简介
There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is …
学术搜索中的文章
ME Dieterle, D Haslwanter, RH Bortz, AS Wirchnianski… - Cell host & microbe, 2020